Back

Apnimed advances AD109 toward commercialization after strong Phase 3 results

Verifying
  • Apnimed is advancing AD109, also known as Oxnimbi, for obstructive sleep apnea.
  • Apnimed says AD109 showed an advantage over CPAP therapy in Phase 3 results.
  • The company has a fully funded commercialization plan and an NDA under FDA review.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.